Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report
Abstract Background The efficacy of epidermal growth factor receptor EGFR tyrosine kinase inhibitors in cholangiocarcinoma (CCA) patients is still unknown. Here, we report a 67-year-old CCA patient with EGFR exon 19 deletion receiving afatinib treatment. Case description A 67-year-old male was refer...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-04-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02271-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850202351776825344 |
|---|---|
| author | Caijiu Deng Junming Huang Qian Yu Jianjun Han Yuanxue Jiang Liping Lin Xiaolong Cao |
| author_facet | Caijiu Deng Junming Huang Qian Yu Jianjun Han Yuanxue Jiang Liping Lin Xiaolong Cao |
| author_sort | Caijiu Deng |
| collection | DOAJ |
| description | Abstract Background The efficacy of epidermal growth factor receptor EGFR tyrosine kinase inhibitors in cholangiocarcinoma (CCA) patients is still unknown. Here, we report a 67-year-old CCA patient with EGFR exon 19 deletion receiving afatinib treatment. Case description A 67-year-old male was referred to our hospital due to persistent abdominal pain for 3 months. Abdominal computed tomography showed a tumor with a diameter of 92 mm in the left liver with multiple intrahepatic metastases. Immunohistochemistry revealed that tumor cells were positive for CK7 and CK19, and negative for hepatocyte and CDX- 2. A pathological diagnosis of intrahepatic CCA was made. Since the patient declined standard chemotherapy, afatinib was administered as the first-line treatment. Upon disease progression, apatinib was introduced. Unfortunately, the patient ultimately succumbed to hepatic failure, with a total survival of 1.8 months. Conclusion In this report, the CCA patient with EGFR exon 19 deletion was unresponsive to afatinib treatment. However, genetic testing may be still worthwhile for CCA to increase the possible treatment options. |
| format | Article |
| id | doaj-art-fb646126aa19437ea8491f5b8cbf577d |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-fb646126aa19437ea8491f5b8cbf577d2025-08-20T02:11:47ZengSpringerDiscover Oncology2730-60112025-04-011611710.1007/s12672-025-02271-2Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case reportCaijiu Deng0Junming Huang1Qian Yu2Jianjun Han3Yuanxue Jiang4Liping Lin5Xiaolong Cao6Department of Oncology, The Affiliated Panyu Central Hospital, Guangzhou Medical UniversityDepartment of Oncology, Panyu Hospital of Chinese MedicineDepartment of Pathology, The Affiliated Panyu Central Hospital, Guangzhou Medical UniversityDepartment of Oncology, The Affiliated Panyu Central Hospital, Guangzhou Medical UniversityDepartment of Oncology, The Affiliated Panyu Central Hospital, Guangzhou Medical UniversityDepartment of Oncology, The Affiliated Panyu Central Hospital, Guangzhou Medical UniversityDepartment of Oncology, The Affiliated Panyu Central Hospital, Guangzhou Medical UniversityAbstract Background The efficacy of epidermal growth factor receptor EGFR tyrosine kinase inhibitors in cholangiocarcinoma (CCA) patients is still unknown. Here, we report a 67-year-old CCA patient with EGFR exon 19 deletion receiving afatinib treatment. Case description A 67-year-old male was referred to our hospital due to persistent abdominal pain for 3 months. Abdominal computed tomography showed a tumor with a diameter of 92 mm in the left liver with multiple intrahepatic metastases. Immunohistochemistry revealed that tumor cells were positive for CK7 and CK19, and negative for hepatocyte and CDX- 2. A pathological diagnosis of intrahepatic CCA was made. Since the patient declined standard chemotherapy, afatinib was administered as the first-line treatment. Upon disease progression, apatinib was introduced. Unfortunately, the patient ultimately succumbed to hepatic failure, with a total survival of 1.8 months. Conclusion In this report, the CCA patient with EGFR exon 19 deletion was unresponsive to afatinib treatment. However, genetic testing may be still worthwhile for CCA to increase the possible treatment options.https://doi.org/10.1007/s12672-025-02271-2CholangiocarcinomaEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI)EGFR exon 19 deletionAfatinib |
| spellingShingle | Caijiu Deng Junming Huang Qian Yu Jianjun Han Yuanxue Jiang Liping Lin Xiaolong Cao Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report Discover Oncology Cholangiocarcinoma Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) EGFR exon 19 deletion Afatinib |
| title | Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report |
| title_full | Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report |
| title_fullStr | Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report |
| title_full_unstemmed | Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report |
| title_short | Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report |
| title_sort | intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to afatinib monotherapy a case report |
| topic | Cholangiocarcinoma Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) EGFR exon 19 deletion Afatinib |
| url | https://doi.org/10.1007/s12672-025-02271-2 |
| work_keys_str_mv | AT caijiudeng intrahepaticcholangiocarcinomapatientwithepidermalgrowthfactorreceptorexon19deletionunresponsivetoafatinibmonotherapyacasereport AT junminghuang intrahepaticcholangiocarcinomapatientwithepidermalgrowthfactorreceptorexon19deletionunresponsivetoafatinibmonotherapyacasereport AT qianyu intrahepaticcholangiocarcinomapatientwithepidermalgrowthfactorreceptorexon19deletionunresponsivetoafatinibmonotherapyacasereport AT jianjunhan intrahepaticcholangiocarcinomapatientwithepidermalgrowthfactorreceptorexon19deletionunresponsivetoafatinibmonotherapyacasereport AT yuanxuejiang intrahepaticcholangiocarcinomapatientwithepidermalgrowthfactorreceptorexon19deletionunresponsivetoafatinibmonotherapyacasereport AT lipinglin intrahepaticcholangiocarcinomapatientwithepidermalgrowthfactorreceptorexon19deletionunresponsivetoafatinibmonotherapyacasereport AT xiaolongcao intrahepaticcholangiocarcinomapatientwithepidermalgrowthfactorreceptorexon19deletionunresponsivetoafatinibmonotherapyacasereport |